Methotrexate-associated liver toxicity in a patient with breast cancer: Case report and literature review

Netherlands Journal of Medicine

Volumn 60, Issue 5, 2002, Pages 216-222

  van Outryve, S ^a   Schrijvers, D ^a   van den Brande, J ^a   Wilmes, P ^a   Bogers, J ^a   van Marck, E ^a   Vermorken, J B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BENZODIAZEPINE DERIVATIVE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; MITOXANTRONE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; ASTHENIA; BLOOD ANALYSIS; BREAST CANCER; BREAST SURGERY; CANCER RADIOTHERAPY; CASE REPORT; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER TOXICITY; LYMPH NODE DISSECTION; MEDICAL LITERATURE; SYMPTOMATOLOGY; TOXIC HEPATITIS; BREAST TUMOR; MIDDLE AGED; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HEPATITIS, TOXIC; HUMANS; METHOTREXATE; MIDDLE AGED; MITOXANTRONE;

EID: 0036617233     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remissions in acute leukemia in children produced by folic antagonist 4-aminopteroylglutamic acid (aminopterin). N Engl J Med 1948;238:787-93.
2. Hansen HH, Selawry OS, Holland JF, McCall CB. The variability of individual tolerance to methotrexate in cancer patients. Br J Cancer 1971;25:298-305.
3. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332:292-7.
4. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998;29:990-3.
5. Knox TA, Kaplan MM, Gelfand JA, Wolff SM. Methotrexate treatment of idiopathic granulomatous hepatitis. Ann Intern Med 1995;122:592-5.
6. Tett SE, Triggs EJ. Use of methotrexate in older patients. A risk-benefit assessment. Drugs Aging 1996;9:458-71.
7. Smeland E, Fuskevåg OM, Nymann K, et al. High-dose 7-hydroxymethotrexate: acute toxicity and lethality in a rat model. Cancer Chemother Pharmacol 1996;37:415-22.
8. Allegra CJ, Grem JL. Pharmacology of Cancer Chemotherapy Antimetabolites. In: DeVita VT Jr, Hellman S, Rosenberg S, editors Cancer Principles and Practice of Oncology. Philadelphia, NY: Lippincott-Raven, 1997. p. 432-52.
9. Alkins SA, Byrd JC, Morgan SK, Ward FT, Weiss RB. Anaphylactoid reactions to methotrexate. Cancer 1996;77:2123-6.
10. Lamki Z al, Thomas E, Banna N el, Jaffe N. Acute urticaria and hepatitis complicating high-dose methotrexate therapy. Med Pediatr Oncol 1995;24:137-40.
11. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987;14:1164-71.
12. Meadows AT, Evans AE. Effects of chemotherapy on the central nervous system. A study of parenteral methotrexate in long-term survivors of leukemia and lymphoma in childhood. Cancer 1976;37:1079-85.
13. Milunsky MB, Graef JW, Gaynor MF. Methotrexate-induced congenital malformations. With a review of the literature. J Pediatr 1968;72:790-5.
14. Perez C, Suto WW, Wang YM, Herson J. Evaluation of overall toxicity of high-dose methotrexate regimens. Med Pediatr Oncol 1979;6:219-28.
15. Zachariae H, Kragballe K, Sogaard H. Methotrexate induced cirrhosis. Studies including serial liver biopsies during continued treatment. Br J Dermatol 1980;102:407-12.
16. Rask C, Albertioni F, Bentzen SM, Schroeder H, Peterson C. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with ALL - a logistic regression analysis. Acta Oncol 1998;37:277-84.
17. Perry MC. Hepatotoxicity of Chemotherapeutic Agents. Semin Oncol 1982;9:65-74.
18. Scheufler E, Zetler G, Iven H. Pharmacokinetics and organ distribution of methotrexate in the rat. Pharmacology 1981;23:75-81.
19. Horne DW, Briggs WT, Wagner C. A functional, active transport system for methotrexate in freshly isolated hepatocytes. Biochem Biophys Res Commun 1976;68:70-6.
20. Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 1978;3:1-13.
21. Baugh CM, Krumdieck CL, Nair MG. Polygammaglutamyl metabolites of methotrexate. Biochem Biophys Res Commun 1973;52:27-34.
22. Kamen BA, Nylen PA, Camitta BM, Bertino JR. Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug. Br J Haematol 1981;49:355-60.
23. Schalinske KL, Steele RD. Methotrexate alters carbon flow through the hepatic folate-dependent one-carbon pool in rats. Carcinogenesis 1996;17:1695-700.
24. Hopwood D, Nyfors A. Effect of methotrexate therapy in psoriatics on the Ito cells in liver biopsies, assessed by point-counting. J Clin Pathol 1976;29:698-703.
25. Gressner AM. Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. Kidney Int Suppl 1996;54(suppl):S39-S45.
26. Newman M, Auerbach R, Feiner H, et al. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment. Arch Dermatol 1989;125:1218-24.
27. Roenigk HH Jr, Bergfeld WF, Jacques RS, Owens FJ, Hawk WA. Hepatotoxicity of methotrexate in the treatment of psoriasis. Arch Dermatol 1971;103:250-61.
28. Mitchell D, Smith A, Rowan B, et al. Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate. Br J Dermatol 1990;122:1-7.
29. Birnie GG, Fitzsimons CP, Czarnecki D, Cooke A, Scobie G, Brodie MJ. Hepatic metabolic function in patients receiving long-term methotrexate therapy: comparison with topically treated psoriatics, patient controls and cirrhotics. Hepato-gastroenterol 1985;32:163-7.
30. O'Connor GT, Olmstead EM, Zug K, et al. Detection of hepatotoxicity associated with methotrexate therapy for psoriasis. Arch Dermatol 1989;125:1209-17.
31. Farrow AC, Buchanan GR, Zwiener RJ, Bowman WP, Winick NJ. Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol, 1997;15:1560-6.
32. Goodman TA, Polisson RP. Methotrexate: adverse reactions and major toxicities. Rheum Dis Clin North Am 1994;20:513-28.
33. Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37:316-28.
34. Beyeler C, Reichen J, Thomann SR, Lauterburg BH, Gerber NJ. Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol 1997;36:338-44.
35. Fabbri A, Motta E, Ferrari S, et al. High-dose methotrexate treatment and liver function in patients with osteosarcoma. J Intern Med 1994;236:209-14.
36. Vaughan WP, Wilcox PM, Alderson PO, Ettinger DS, Abeloff MD. Hepatic toxicity of adjuvant chemotherapy for carcinoma of the breast. Med Pediatr Oncol 1979;7:351-9.
37. Dolan OM, Burrows D, Irvine A, Walsh M. The value of a baseline liver biopsy prior to methotrexate treatment. Br J Dermatol 1994;131:891-4.
38. The clinical NMR group: University of Aberdeen and Grampian Health Board. Magnetic resonance imaging of parenchymal liver disease: a comparison with ultrasound, radionuclide scintigraphy and X-ray computed tomography. Clin Radiol 1987;38:495-502.
39. West SC. Methotrexate hepatotoxicity. Rheum Dis Clin North Am 1997;23:883-915.
40. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988;19:145-56.
41. Chevallier M, Guerret S, Chossegros P, Gerard F, Grimaud JA. A histological semi-quantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. Hepatology 1994;20:349-55.
42. Roenigk HH Jr, Maibach HI, Weinstein GD. Use of methotrexate in psoriasis. Arch Dermatol 1972;105:363-5.
43. Roenigk HH Jr, Maibach HI, Weinstein GP. Methotrexate therapy for psoriasis. Guideline revisions. Arch Dermatol 1973;108:35.
44. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate guidelines-revised. J Am Acad Dermatol 1982;6:145-55.
45. Smith TJ, Davidson NE, Schapira DV, et al. American society of clinical oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999;17:1080-2.
46. Faggioli P, Paschale M de, Tocci A, et al. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma. Haematologica 1997;82:38-42.
47. Wong GC, Tan P, Goh YT, Ng HS, Chong R, Lee LH. Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. Ann Acad Med Singapore 1996;25:500-3.
48. Coleiro B, Mallia C. Toxicity proflie of methotrexate in rheumatoid arthritis. A preliminary survey. Adv Exp Med Biol 1999;455:359-65.
49. Troché G, Sacquin P, Achkar A, Korach JM, Laaban JP, Gajdos Ph. Intoxication grave au méthotrexate. Presse Med 1991;20:1724-7.
50. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histological hepatic abnormalities: a meta-analysis. Am J Med 1991;90:711-6.
51. Panasci L, Polizzi G, Palmer S. Diminished toxicity of methotrexate in CD2F1 mice pretreated with cycloheximide. Cancer Lett 1982;15:81-6.
52. Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 1983;52:1986-92.
53. Bajetta E, Buzzoni R, Giardini R, Bonadonna G. Liver assessment in women receiving adjuvant CMF chemotherapy. Tumori 1981;67:27-30.
54. Wolff JE, Hauch H, Kühl J, Egeler RM, Jürgens H. Dexamethasone increases hepatotoxicity of MTX in children with brain tumors. Anticancer Res 1998;18:2895-900.
55. Honjo I, Suou T, Hirayama C. Hepatotoxicity of cyclophosphamide in man: pharmacokinetic analysis. Res Commun Chem Pathol Pharmacol 1988;61:149-65.
56. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol 1993;11:2386-90.
57. Hirvikoski PP, Kumpulainen EJ, Johansson RT. Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen. Breast Cancer Res Treat 1997;44:269-74.
58. Faulds D, Balfour JA, Chrisp P, Langtry HD. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991;41:400-49.
59. Chlebowski RT, Bulcavage L, Henderson IC, Woodcock T, Rivest R, Elashoff R. Mitoxantrone use in breast cancer patients with elevated bilirubin. Breast Cancer Res Treat 1989;14:267-74.